1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
NAVCO Pharmaceuticals Inc

NAVCO Pharmaceuticals Inc

NAV.V
NAVCO Pharmaceuticals IncCA flagToronto Stock Exchange Ventures
0.01
CAD
- -
- -
285,348.00Market Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2022 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.11
-0.02
-0.03
-0.04
- -
-0.02
Free Cash Flow per Basic Share
- -
-0.05
-0.02
-0.03
- -
- -
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.02
0.05
0.04
0.02
- -
- -
- -
Tangible Book Value per Share
0.02
0.05
0.04
0.02
- -
- -
- -
Basic Weighted Avg Shares
- -
2
2
3
3
14
3
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-118.9
-26.65
-57.34
-186.2
- -
-171.68

Capital Structure

FRC

•

in mil. unless spec.
Sep'22
Dec'23
Mar'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'22
Dec'23
Mar'23
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
-0.01
-0.01
- -
-0.03
2022
- -
-0.01
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Geoffrey Lee
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
1170 – 1040 West Georgia Street Vancouver BC Canada V6E 4H1
IPO Date
Nov 8, 2018
Website
navcopharma.com
Similar Companies
Qianhai Health Holdings Limited (0911.HK)
ZhuZhou QianJin Pharmaceutical Co.,Ltd (600479.SS)
American Green, Inc. (ERBB)
Chill Brands Group PLC (CHLL.L)
Captor Capital Corp. (CPTR.CN)
MediPharm Labs Corp. (MEDIF)
Business
Navco Pharmaceuticals Inc. is a Canada-based pharmaceutical and nanotechnology company that researches, develops, manufactures and commercializes supplemental and therapeutic consumer health and wellness products for antibacterial support, immunity support and infectious disease prevention; its product portfolio includes aerosol sprays, hand cleansers, hand creams, disinfectant sprays and nano BioGuard silver-based products, together with diagnostic testing, PPE, textile and food-related solutions used across medical, personal care, textile, chemical and additive applications. Founded in 2018 and headquartered in Vancouver, British Columbia, the company operates through a business model focused on nanotechnology-enabled products and materials and serves customers in Canada and other international markets through its health, hygiene and industrial product offerings. In the latest major corporate developments, Navco completed the acquisition of SL Immuno Pharma Corp. in January 2024, expanding its pharmaceutical and health-product platform; the company also continued to progress from its earlier reverse takeover and name change from BMGB Capital Corp., which established the current NAVCO Pharmaceuticals Inc. structure and TSX Venture Exchange listing.